Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000077.xml
Download PDF
Semin Thromb Hemost 2007; 33(8): 798-809
DOI: 10.1055/s-2007-1000372
DOI: 10.1055/s-2007-1000372
Hemostatic Dysfunction Associated with Endocrine Disorders as a Major Risk Factor and Cause of Human Morbidity and Mortality: A Comprehensive Meta-review
Further Information
Publication History
Publication Date:
04 January 2008 (online)
ABSTRACT
We review the association between disorders of endocrine function and hemostasis. The content of more than 570 review articles were appraised to provide the core of 81 key articles referenced in this chapter. The search method used MEDLINE and EMBASE electronic databases and the key words endocrine dysfunction, diabetes, Graves' disease, hypothyroidism, hyperthyroidism, thyrotoxicosis, von Willebrand disease, von Willebrand factor, bleeding disorders, platelets dysfunction, hemostasis dysfunction, and review. Abnormalities of hemostasis, platelets, and endothelium and the presence of microparticles, abnormal expression of adhesion molecules, and elevated von Willebrand factor are all associated with cardiovascular disease and are also features of various endocrine disorders, including diabetes and its complications, insulin resistance, polycystic ovary syndrome, and various thyroid disorders. Related causes and associated factors, including obesity, alcohol, hyperlipidemia, omega fatty acids, vitamin D, serotonin, insulin-like growth factors, angiotensin-converting enzyme, and C-reactive protein, are also discussed in this review.
KEYWORDS
Adhesion molecules - endocrine disorders - endothelium - hemostasis - platelets
REFERENCES
- 1 Tomoriova E, Tkac I, Takac M. Hypercoagulation states. Vnitr Lek. 1993; 39 1114-1119
- 2 Schafer A I. The hypercoagulable states. Ann Intern Med. 1985; 102 814-828
- 3 Palumbo P J. Metformin: effects on cardiovascular risk factors in patients with non-insulin-dependent diabetes mellitus. J Diabetes Complications. 1998; 12 110-119
- 4 Sowers J R. Diabetes mellitus and cardiovascular disease in women. Arch Intern Med. 1998; 158 617-621
- 5 Clemetson K J. Platelet receptors and their role in diseases. Clin Chem Lab Med. 2003; 41 253-260
- 6 Packham M A, Mustard J F. The role of platelets in the development and complications of atherosclerosis. Semin Hematol. 1986; 23 8-26
- 7 Nordt T K, Bode C. Endothelium and endogenous fibrinolysis. Z Kardiol. 2000; 89 219-226
- 8 Becker B F, Heindl B, Kupatt C, Zahler S. Endothelial function and hemostasis. Z Kardiol. 2000; 89 160-167
- 9 Sumpio B E, Riley J T, Dardik A. Cells in focus: endothelial cell. Int J Biochem Cell Biol. 2002; 34 1508-1512
- 10 Nabel E G. Biology of the impaired endothelium. Am J Cardiol. 1991; 68 6C-8C
- 11 Berkenboom G. Vascular endothelium: target organ of cardiovascular pathologies. Ann Cardiol Angeiol (Paris). 1999; 48 643-646
- 12 Mancini M, Rubba P. Ischemic cardiopathy: risk factors and their biological role. Ital Heart J. 2000; 1(Suppl 2) 17-22
- 13 Simon B C, Noll B, Maisch B. Endothelial dysfunction-assessment of current status and approaches to therapy. Herz. 1999; 24 62-71
- 14 Willerson J T. Conversion from chronic to acute coronary heart disease syndromes. Role of platelets and platelet products. Tex Heart Inst J. 1995; 22 13-19
- 15 Vallance P, Calver A, Collier J. The vascular endothelium in diabetes and hypertension. J Hypertens Suppl. 1992; 10 S25-S29
- 16 Mehta J L, Nicolini F A, Donnelly W H, Nichols W W. Platelet-leukocyte-endothelial interactions in coronary artery disease. Am J Cardiol. 1992; 69 8B-13B
- 17 Harrison D G, Kurz M A, Quillen J E, Sellke F W, Mugge A. Normal and pathophysiologic considerations of endothelial regulation of vascular tone and their relevance to nitrate therapy. Am J Cardiol. 1992; 70 11B-17B
- 18 Pomilio M, Mohn A, Verrotti A, Chiarelli F. Endothelial dysfunction in children with type 1 diabetes mellitus. J Pediatr Endocrinol Metab. 2002; 15 343-361
- 19 Horstman L L, Jy W, Jimenez J J, Ahn Y S. Endothelial microparticles as markers of endothelial dysfunction. Front Biosci. 2004; 9 1118-1135
- 20 Krieglstein C F, Granger D N. Adhesion molecules and their role in vascular disease. Am J Hypertens. 2001; 14 44S-54S
- 21 Blann A D. Plasma von Willebrand factor, thrombosis, and the endothelium: the first 30 years. Thromb Haemost. 2006; 95 49-55
- 22 Blann A D, McCollum C N. von Willebrand factor, endothelial cell damage and atherosclerosis. Eur J Vasc Surg. 1994; 8 10-15
- 23 Blann A. Willebrand factor and the endothelium in vascular disease. Br J Biomed Sci. 1993; 50 125-134
- 24 Lip G Y, von Blann A. Willebrand factor: a marker of endothelial dysfunction in vascular disorders?. Cardiovasc Res. 1997; 34 255-265
- 25 van Mourik J A, Romani de Wit T. Von Willebrand factor propeptide in vascular disorders. Thromb Haemost. 2001; 86 164-171
- 26 Nitu-Whalley I C, Lee C A. Acquired von Willebrand syndrome-report of 10 cases and review of the literature. Haemophilia. 1999; 5 318-326
- 27 Rinder M R, Richard R E, Rinder H M. Acquired von Willebrand's disease: a concise review. Am J Hematol. 1997; 54 139-145
- 28 Jakway J L. Acquired von Willebrand's disease. Hematol Oncol Clin North Am. 1992; 6 1409-1419
- 29 Delonca J, Balteaux V, Giraud T, Sanchez R Y. EDRF/NO and endothelial functions. Arch Mal Coeur Vaiss. 1993; 86 1617-1624
- 30 Hunley T E, Iwasaki S, Homma T, Kon V. Nitric oxide and endothelin in pathophysiological settings. Pediatr Nephrol. 1995; 9 235-244
- 31 Vapaatalo H, Mervaala E. Clinically important factors influencing endothelial function. Med Sci Monit. 2001; 7 1075-1085
- 32 Naseem K M. The role of nitric oxide in cardiovascular diseases. Mol Aspects Med. 2005; 26 33-65
- 33 Rush J W, Denniss S G, Graham D A. Vascular nitric oxide and oxidative stress: determinants of endothelial adaptations to cardiovascular disease and to physical activity. Can J Appl Physiol. 2005; 30 442-474
- 34 Banfi C, Mussoni L, Tremoli E. PAI-1, the primary plasmatic inhibitor of fibrinolysis. Physiopathologic role and molecular mechanisms. Minerva Endocrinol. 2002; 27 181-191
- 35 De Pergola G, Pannacciulli N. Coagulation and fibrinolysis abnormalities in obesity. J Endocrinol Invest. 2002; 25 899-904
- 36 Malenfant M. Diabetic retinopathy: pathogenesis, risk factors, clinical picture, classification. Bull Soc Belge Ophtalmol. 1995; 256 11-23
- 37 Hano T, Nishio I. Hypertension in the patients with impaired glucose tolerance. Nippon Rinsho. 1996; 54 2687-2691
- 38 Schneider D J, Nordt T K, Sobel B E. Attenuated fibrinolysis and accelerated atherogenesis in type II diabetic patients. Diabetes. 1993; 42 1-7
- 39 Kohler H P. Insulin resistance syndrome: interaction with coagulation and fibrinolysis. Swiss Med Wkly. 2002; 132 241-252
- 40 Wirth A, Rothenfelde B. Metabolic syndrome. Versicherungsmedizin. 1996; 48 193-199
- 41 Dunn E J, Grant P J. Type 2 diabetes: an atherothrombotic syndrome. Curr Mol Med. 2005; 5 323-332
- 42 Banga J D. Coagulation and fibrinolysis in diabetes. Semin Vasc Med. 2002; 2 75-86
- 43 Frohlich J, Steiner G. Dyslipidaemia and coagulation defects of insulin resistance. Int J Clin Pract Suppl. 2000; 113 14-22
- 44 Ghosh K. Thrombohaemorrhagic balance in diabetes mellitus. J Indian Med Assoc. 2002; 100 428-433
- 45 Ferrannini E, Galvan A Q, Gastaldelli A et al.. Insulin: new roles for an ancient hormone. Eur J Clin Invest. 1999; 29 842-852
- 46 Juhan-Vague I, Alessi M C, Vague P. Thrombogenic and fibrinolytic factors and cardiovascular risk in non-insulin-dependent diabetes mellitus. Ann Med. 1996; 28 371-380
- 47 Janka H U. Insulin resistance and cardiovascular complications. Wien Klin Wochenschr. 1994; 106 758-762
- 48 Blann A D, Lip G Y. Endothelial integrity, soluble adhesion molecules and platelet markers in type 1 diabetes mellitus. Diabet Med. 1998; 15 634-642
- 49 Porta M, Molinatti P, La Selva M, Molinatti G M. Endothelium and its morphofunctional changes in the pathogenesis of diabetic microangiopathy. Minerva Med. 1988; 79 915-929
- 50 McMillan D E. The effect of diabetes on blood flow properties. Diabetes. 1983; 32(Suppl 2) 56-63
- 51 Carr M E. Diabetes mellitus: a hypercoagulable state. J Diabetes Complications. 2001; 15 44-54
- 52 McDonagh P F, Hokama J Y. Microvascular perfusion and transport in the diabetic heart. Microcirculation. 2000; 7 163-181
- 53 Sobol A B, Watala C. The role of platelets in diabetes-related vascular complications. Diabetes Res Clin Pract. 2000; 50 1-16
- 54 Varughese G I, Tomson J, Lip G Y. Type 2 diabetes mellitus: a cardiovascular perspective. Int J Clin Pract. 2005; 59 798-816
- 55 Luscher T F, Oemar B S, Yang Z, Noll G. Molecular and cellular mechanisms of arteriosclerosis and restenosis: possibilities of gene therapy. Z Kardiol. 1996; 85 495-508
- 56 Stratmann B, Tschoepe D. Pathobiology and cell interactions of platelets in diabetes. Diab Vasc Dis Res. 2005; 2 16-23
- 57 Arjomand H, Roukoz B, Surabhi S K, Cohen M. Platelets and antiplatelet therapy in patients with diabetes mellitus. J Invasive Cardiol. 2003; 15 264-269
- 58 Colwell J A, Nesto R W. The platelet in diabetes: focus on prevention of ischemic events. Diabetes Care. 2003; 26 2181-2188
- 59 Kirpichnikov D, Sowers J R. Diabetes mellitus and diabetes-associated vascular disease. Trends Endocrinol Metab. 2001; 12 225-230
- 60 Savage P J. Treatment of diabetes mellitus to reduce its chronic cardiovascular complications. Curr Opin Cardiol. 1998; 13 131-138
- 61 McMillan D E. Deterioration of the microcirculation in diabetes. Diabetes. 1975; 24 944-957
- 62
Kessler L, Wiesel M L, Attali P, Mossard J M, Cazenave J P, Pinget M.
Von Willebrand factor in diabetic angiopathy.
Diabetes Metab.
1998;
24
327-336
MissingFormLabel
- 63 Porta M, La Selva M, Molinatti P A. von Willebrand factor and endothelial abnormalities in diabetic microangiopathy. Diabetes Care. 1991; 14 167-172
- 64 Bell D S. Alcohol and the NIDDM patient. Diabetes Care. 1996; 19 509-513
- 65 Lyons D. Impairment and restoration of nitric oxide-dependent vasodilation in cardiovascular disease. Int J Cardiol. 1997; 62(Suppl 2) S101-S109
- 66 Simopoulos A P. Omega-3 fatty acids in health and disease and in growth and development. Am J Clin Nutr. 1991; 54 438-463
- 67 Gerster H. Prevention of platelet dysfunction by vitamin E in diabetic atherosclerosis. Z Ernahrungswiss. 1993; 32 243-261
- 68 Hirano T. Lipoprotein abnormalities in diabetic nephropathy. Kidney Int Suppl. 1999; 71 S22-S24
- 69 Lobo R A, Carmina E. The importance of diagnosing the polycystic ovary syndrome. Ann Intern Med. 2000; 132 989-993
- 70 Zdrojewicz Z, Sztuka-Pietkiewicz A, Zarzycki A, Karwacki J. Serotonin-structure, activity and clinical significance. Postepy Hig Med Dosw. 1998; 52 637-654
- 71 McCarty M F. Up-regulation of endothelial nitric oxide activity as a central strategy for prevention of ischemic stroke - just say NO to stroke!. Med Hypotheses. 2000; 55 386-403
- 72 Ferns G A, Motani A S, Anggard E E. The insulin-like growth factors: their putative role in atherogenesis. Artery. 1991; 18 197-225
- 73 Tschudi M R, Noll G, Luscher T P. Pharmacotherapy of arteriosclerosis and its complications. Effect of ACE inhibitors and HMG-CoA-reductase inhibitors. Schweiz Med Wochenschr. 1997; 127 636-649
- 74 Mombouli J V. ACE inhibition, endothelial function and coronary artery lesions. Role of kinins and nitric oxide. Drugs. 1997; 54(Suppl 5) 12-22
- 75 Koppel H, Eber B, Gasser R, Klein W. Recent molecular and pharmacologic aspects of ACE inhibitors. Wien Med Wochenschr. 1995; 145 633-637
- 76 Ridker P M. Intrinsic fibrinolytic capacity and systemic inflammation: novel risk factors for arterial thrombotic disease. Haemostasis. 1997; 27(Suppl 1) 2-11
- 77 Klein M, Barbe F, Kaminsky P, Duc M. Disorders of hemostasis in dysthyroidism. Pathol Biol (Paris). 1993; 41 268-275
- 78 Ford H C, Carter J M. Haemostasis in hypothyroidism. Postgrad Med J. 1990; 66 280-284
- 79 Squizzato A, Romualdi E, Buller H R, Gerdes V E. Clinical review: thyroid dysfunction and effects on coagulation and fibrinolysis: a systematic review. J Clin Endocrinol Metab. 2007; 92 2415-2420
- 80 Squizzato A, Gerdes V E, Ageno W, Buller H R. The coagulation system in endocrine disorders: A narrative review. Intern Emerg Med. 2007; 2 76-83
- 81 Michiels J J, Schroyens W, Berneman Z, van der Planken M. Acquired von Willebrand syndrome type 1 in hypothyroidism: reversal after treatment with thyroxine. Clin Appl Thromb Hemost. 2001; 7 113-115
Ashraf Mina
Institute of Clinical Pathology and Medical Research (ICPMR)
Westmead Hospital, Westmead, N.S.W. 2145, Australia
Email: ashraf.mina@swahs.health.nsw.gov.au